In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Activist Shareholders Complicate Buyout Math

Executive Summary

The efforts of an increasingly vocal group of activist shareholders, including Carl Icahn, Matrix Asset Advisors, Third Point, ValueAct, and Baker Brothers Advisors, to flush out the interest of strategic buyers has become compelling and increasingly commonplace.

You may also be interested in...



Capital Allocation In The Age Of Shareholder Activism

Maybe no company is safe from activists, but there are protective measures that managers and boards can take. What biopharmas can learn from Valeant Pharmaceuticals and Pershing Square’s pursuit of Allergan.

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2007

In this issue, we present another installment of our quarterly review of pharmaceutical/biotechnology dealmaking-for April-June 2007. Our data come from Windhover's Strategic Transactions Database. Look for our quarterly review on the medical device, in vitro diagnostics, and research industries in upcoming issues.

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2007

In this issue, we present another installment of our quarterly review of pharmaceutical/biotechnology dealmaking-for April-June 2007. Our data come from Windhover's Strategic Transactions Database. Look for our quarterly review on the medical device, in vitro diagnostics, and research industries in upcoming issues.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC031354

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel